Mark L. Sobczak, MD

Mark Sobczak
  • Chief Network Officer
  • Associate Medical Director
  • Vice President


The Partners program promotes timely translation of research findings to ensure patients have access to the latest advances in cancer care and treatment.

Dr. Sobczak joined the Fox Chase Cancer Center after a notable career in the US Navy Medical Corps, where he organized ,and then led, the first comprehensive oncology department in military medicine. This was followed by years of experience in the planning, development, and growth of free-standing radiation oncology centers with 21st Century Oncology. Dr. Sobczak has been a pioneer in the planning, implementation and utilization of electronic medical records in Oncology. He is board certified in Radiation Oncology through the American Board of Radiology. In 1991 Dr. Sobczak was a finalist in the astronaut mission specialist selection process for NASA. 

Mark L. Sobczak, MD, was born and raised in the near north suburbs of Chicago, Illinois. Dr. Sobczak was an Honors graduate of the Naval Academy with the Class of 1977. Following graduation he completed naval aviation flight training in Florida and Texas, and then served as a Navy pilot for six years prior to entering medical school.

He attended the Uniformed Services University of the Health Sciences where he earned his medical degree in 1987. He continued his post-graduate medical education in Radiation Oncology in the Massachusetts General Hospital/Harvard program where he was named an American Cancer Society Fellow. 

After residency, Dr. Sobczak returned to active duty in the United States Navy Medical Corps. In 1991 he was a finalist for the Astronaut program as a NASA Mission Specialist. He became board certified in Therapeutic Radiology in 1992. In 2001, Dr. Sobczak completed a distinguished career in military medicine and retired from the United States Navy after 24 years of service to his country.

Currently Dr. Sobczak serves as a member of the Genitourinary Steering Committee of the Radiation Therapy Oncology Group where he also acts as a full member site auditor. He is also a member of the Board of Trustees of the Delaware Breast Cancer Coalition. His research interests include predictive biomarkers for genitourinary cancers and cancer prevention and control.